GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment. Recent advancements in GIST treatment include multiple TKIs, such as Sutent, ...
These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations. Unfavorable trends in the diagnosis ...
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun. Gastrointestinal stromal tumor (GIST) is a rare type of ...
Gastrointestinal stromal tumors (GISTs) have increased in incidence over the past two decades, with notable survival disparities among racial and ethnic groups, particularly among Black patients who ...
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
The combination regimen significantly improved progression-free survival and objective response rates in patients who were intolerant to or failed prior imatinib therapy ...
Effect of BRCA2, BRAF, APC, and PTEN expression on the prognostic significance of surgical margin status in primary gastric adenocarcinoma. Impact of pathological complete response after DCF ...
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results